KYMERA THERAPEUTICS, INC. (KYMR) Spending and interest coverage
- R&D / revenue · 12 months: Value 357.68%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 62.10%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 357.68% | Research and development expense / revenue. Period ending 2026-06-30. $375.57M ÷ $105.00M × 100 ≈ 357.68% |
| Stock-based compensation / revenue · 12 months | 62.10% | Share-based compensation / revenue. Period ending 2026-06-30. $65.20M ÷ $105.00M × 100 ≈ 62.10% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 375.57M USD | Research and Development Expense |
| Revenue | 105.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 65.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -350.18M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $375.57M | $105.00M | $65.20M | $-350.18M | (m) | 357.68% | 62.10% | (m) | (m) |
| 2026-03-31 | $334.48M | $51.48M | $61.68M | $-359.13M | (m) | 649.77% | 119.82% | (m) | (m) |
| 2025-12-31 | $316.57M | $39.21M | $59.90M | $-349.40M | (m) | 807.34% | 152.77% | (m) | (m) |
| 2025-09-30 | $304.55M | $43.73M | $59.25M | $-332.26M | (m) | 696.36% | 135.48% | (m) | (m) |
| 2025-06-30 | $290.87M | $44.71M | $58.35M | $-311.86M | (m) | 650.56% | 130.51% | (m) | (m) |
| 2025-03-31 | $271.68M | $58.88M | $57.28M | $-278.23M | (m) | 461.38% | 97.27% | (m) | (m) |
| 2024-12-31 | $240.25M | $47.07M | $55.01M | $-261.63M | (m) | 510.38% | 116.87% | (m) | (m) |
| 2024-09-30 | $221.40M | $87.56M | $52.11M | $-200.19M | (m) | 252.85% | 59.51% | (m) | (m) |
| 2024-06-30 | $209.11M | $88.55M | $48.86M | $-185.58M | (m) | 236.15% | 55.18% | (m) | (m) |
| 2024-03-31 | $195.67M | $79.41M | $45.70M | $-178.03M | (m) | 246.40% | 57.55% | (m) | (m) |
| 2023-12-31 | $189.08M | $78.59M | $43.12M | $-165.53M | (m) | 240.59% | 54.86% | (m) | (m) |
| 2023-09-30 | $179.24M | $46.85M | $41.13M | $-184.85M | (m) | 382.62% | 87.80% | (m) | (m) |
| 2023-06-30 | $175.00M | $51.67M | $38.55M | $-172.22M | (m) | 338.70% | 74.61% | (m) | (m) |
| 2023-03-31 | $170.53M | $46.67M | $36.99M | $-169.65M | (m) | 365.40% | 79.26% | (m) | (m) |
| 2022-12-31 | $164.25M | $46.83M | $35.48M | $-161.26M | (m) | 350.76% | 75.77% | (m) | (m) |
| 2022-09-30 | $158.64M | $45.96M | $35.25M | $-156.62M | (m) | 345.16% | 76.69% | (m) | (m) |
| 2022-06-30 | $153.07M | $56.75M | $33.57M | $-140.38M | (m) | 269.75% | 59.16% | (m) | (m) |
| 2022-03-31 | $147.00M | $63.75M | $29.67M | $-124.29M | (m) | 230.58% | 46.54% | (m) | (m) |
| 2021-12-31 | $137.02M | $72.83M | $24.97M | $-100.53M | (m) | 188.13% | 34.29% | (m) | (m) |
| 2021-09-30 | $119.88M | $70.34M | $18.12M | $-79.32M | (m) | 170.42% | 25.76% | (m) | (m) |
| 2021-06-30 | $97.35M | $64.54M | $13.05M | $-58.76M | (m) | 150.84% | 20.22% | (m) | (m) |
| 2021-03-31 | $75.95M | $49.31M | $7.99M | $-48.23M | (m) | 154.03% | 16.21% | (m) | (m) |
| 2020-12-31 | $62.10M | $34.03M | $5.19M | $-46.30M | (m) | 182.48% | 15.25% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $37.16M | $2.93M | $1.20M | $-42.20M | (m) | 1266.46% | 40.76% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |